-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2842 Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231

Program: Oral and Poster Abstracts
Session: 621. Lymphomas: Translational—Molecular and Genetic: Poster II
Hematology Disease Topics & Pathways:
Minimal Residual Disease
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Robert J. Hayashi1*, Michelle L. Hermiston, MD, PhD2, David T. Teachey, MD3,4, Meenakshi Devidas, PhD, MBA5, Brent L. Wood, MD PhD6, Zhiguo Chen, MS7*, Robert D Annett, Ph.D.8*, Barbara L Asselin, MD9, Keith J August, MD, MS10, Steve Y Cho, MD11*, Kimberly P. Dunsmore, MD12*, Jason L. Freedman, MD13*, Paul J. Galardy, MD14, Paul Harker-Murray, MD, PhD15, Terzah M. Horton, MD, PhD16, Alok I Jaju, MD17*, Allison Lam, BCPS18*, Yoav H. Messinger, MD19, Rodney R. Miles, MD, PhD20, Maki Okada, RN18*, Samir I Patel, MD21*, Eric S Schafer, MD22*, Tal Schechter-Finkelstein, MD23, Kristin A. Shimano, MD24, Neelam Singh, PhD25*, Amii C. Steele, PhD26*, Maria Luisa Sulis, MD27, Sarah L Vargas, PhD28*, Stuart S. Winter, MD29, Charlotte Wood, CCRP30*, Patrick A Zweidler-McKay, MD, PhD31, Mignon L. Loh, MD32, Stephen P. Hunger, MD4, Elizabeth A. Raetz, MD33, Catherine M Bollard, MD34 and Carl Allen, MD35

1Pediatric Hematology/Oncology (PD), St Louis, MO
2Pediatric Hematology Oncology, University of California San Francisco, San Francisco, CA
3Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
4Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
5Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN
6Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA
7Department of Biostatistics, University of Florida, Gainesville, FL
8Pediatrics, University of New Mexico, Albuquerque,, NM
9Golisano Children's Hospital at URMC, University of Rochester Strong Memorial Hospital, Rochester, NY
10Chidren's Mercy Hospital, Kansas City, MO
11Wisconsin Institute for Medical Research, Madison, WI
12Virginia Tech Carilion School of Medicine, Roanoke, VA
13Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
14Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN
15Midwest Children's Cancer Center, Milwaukee, WI
16Baylor College of Medicine, Houston, TX
17Lurie Children's Hospital, Chicago, IL
18Miller Children's and Women’s Hospital, Long Beach, CA
19Children's Hospitals and Clinics of Minnesota, Minneapolis, MN
20Dept. of Pathology and ARUP Institute for Clinical & Experimental Pathology, University of Utah, Primary Children's Hospital, Salt Lake City, UT
21University of Alberta- Stollery Children’s Hospital, Edmonton, AB, Canada
22Baylor College of Medicine, Texas Children's Hospital, Houston, TX
23Division of Hematology/Oncology, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada
24Department of Pediatrics, University of California Benioff Children’s Hospital, San Francisco, CA
25Michigan State University Clinical Center, Lansing, MI
26Carolinas Medical Center/Levine Cancer Institute, Charlotte, NC
27Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
28Children's Oncology Group, Monrovia, CA
29Research Institute and Cancer and Blood Disorders Program, Children's Minnesota, Eagan, MN
30Children's Oncology Group Data Center, Gainesville, FL
31ImmunoGen, Inc., Waltham, MA
32Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California Benioff Children’s Hospital, Seattle, WA
33Division of Pediatric Hematology and Oncology, Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, NYU Langone Health, New York, NY
34Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC
35Texas Children's Hospital, Houston, TX

Background: Defining prognostic variables that correlate to EFS in T-LL remains a clinical challenge. Traditional variables such as stage or radiologic response to therapy have failed to correlate with EFS in recent trials. AALL1231 was a COG phase 3 clinical trial for newly diagnosed with T Acute Lymphoblastic leukemia (T-ALL) or T-LL patients that randomized children and young adults (age 1-30 years) to a modified augmented BFM (aBFM) backbone with no bortezomib (Arm A) or with bortezomib (Arm B) during induction and delayed intensification (DI) (1.3mg/m2 x 4 doses per block). T-LL patients were stratified as standard (SR), intermediate (IR), or very high risk (VHR), based upon minimal detectable disease (MDD) in the bone marrow at diagnosis, prior steroid pre-treatment and radiographic response at the end of induction. Bone marrow (BM) samples to assess MRD by flow cytometry at the EOI were an optional submission for T-LL participants and those collected were analyzed to assess its correlation to EFS.

Results: AALL1231 accrued 209 T-LL patients from 2014 until closure in 2017. At the end of induction, 43.6% were in radiologic remission, 55.4% had a partial response and 1% had stable disease or no response. There were 86 (41%) patients for whom EOI samples for MRD assessment were submitted. Patients with MRD <0.1% (n=75) at EOI had a superior EFS versus those with MRD >0.1% (n= 11), (89.0 + 4.4% verses 63.6 + 17.2%, p= 0.025). Overall survival did not significantly differ between the two groups (88.9 + 4.4% versus 72.7 + 15.5% p= 0.15). As previously reported, Arm B demonstrated a superior outcome for both EFS and OS for the entire cohort. Within risk groups, IR and SR patients had similar EFS outcomes (Arm A 73.9 + 7.5% versus 80.4 + 6.7, Arm B 87.2 + 5.8 % versus 90.5 + 4.8%) with only two patients the VHR, both in Arm B. Cox regression for EFS using Arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (Hazard Ratio, HR = 3.73 (1.12-12.40, p = 0.032), (Table 1) which was independent of treatment arm assignment. OS failed to reach statistical significance for patients MRD EOI ≥0.1%, HR = 2.714 (0.72-10.44, p=0.14). Furthermore, Cox regression failed to demonstrate a superior EFS with decreasing MDD at diagnosis (>5% versus 1-5%, versus <1%), HR=2.67 (0.336-21.145, p=0.141, HR= 0.830 (0.255-2.699, HR= 0.57 (0.289-1.073, p= 0.080)(Table 2).

Conclusions: In this pediatric T-LL trial, BM EOI MRD by flow cytometry was associated with improved EFS in in both arms (+/- bortezomib) in both univariate and multivariate analyses. In contrast, race, age, gender, risk group, MDD, stage and radiologic response to therapy were not prognostic. Consideration to incorporate MRD at EOI into the design of future trials will establish its value in defining risk groups for subsequent therapeutic trials.

Disclosures: Hermiston: Sobi: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Teachey: BEAM Therapeutics: Consultancy; Sobi: Consultancy. August: Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Beam Therapeutics: Membership on an entity's Board of Directors or advisory committees. Freedman: Massive Bio, Inc: Consultancy, Current holder of stock options in a privately-held company. Shimano: Dova Pharmaceuticals: Research Funding; Principia Biopharma: Research Funding; Novartis: Research Funding; Pfizer: Research Funding; Daiichi-Sankyo: Research Funding. Zweidler-McKay: ImmunoGen, Inc.: Current Employment. Hunger: Servier: Honoraria; Jazz: Honoraria; Amgen: Honoraria; Amgen: Current equity holder in private company. Raetz: BMS: Other: Data and Safety Monitoring Board; Pfizer: Research Funding. Bollard: Mana Therapeutics: Current equity holder in private company, Current holder of stock options in a privately-held company, Other: scientific ci-founder and SAB member, Patents & Royalties: VSTs/TAA-T; Neximmune: Current equity holder in private company; BMS: Consultancy; SOBI: Other: DSMB member; Catamaran Bio: Current equity holder in private company, Current holder of stock options in a privately-held company, Other: scientific ci-founder and SAB member; Repertoire Immune Medicines: Current equity holder in private company; Cabalatte Bio: Membership on an entity's Board of Directors or advisory committees; Cellmedica: Patents & Royalties; Roche: Consultancy; Pfizer: Consultancy.

*signifies non-member of ASH